Article PDF
Avoid common mistakes on your manuscript.
References
Kim KH, Sim WY, Lew BL. Nivolumab-induced alopecia areata: a case report and literature review. Ann Dermatol 2021; 33: 284–8.
Komatsu-Fujii T, Otsuka A, Ishida Y, et al. Diffuse hair loss following anti-programmed cell death-1 antibody treatment: a case report with immunohistochemical analysis. Eur J Dermatol 2019; 29: 326–7.
Galli G, Proto C, Cossa M, et al. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. Tumori 2019; 105: NP57–62.
Lakhmiri M, Cavelier-Balloy B, Lacoste C, et al. Nivolumab-induced alopecia areata: a reversible factor of good prognosis. JAAD Case Rep 2018; 4: 761–5.
Assi H, Wilson KS. Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. Curr Oncol 2013; 20: e165–9.
Pearson DR, Lewis K, Alkousakis T. Remote-onset alopecia areata attributed to ipilimumab. Cutis 2019; 104: E25–7.
Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190–209.
Guidry J, Brown M, Medina T. PD-1 inhibitor induced alopecia areata. Dermatol Online J 2018; 24: 13030.
Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22: 886–94.
Wang X, Marr AK, Breitkopf T, et al. Hair follicle mesenchyme-associated PD-L1 regulates T-cell activation induced apoptosis: a potential mechanism of immune privilege. J. Invest Dermatol 2014; 134: 736–45.
Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate adaptive immunity. Nature 2010; 466: 113–7.
Wang EHC, Yu M, Breitkopf T, et al. Identification of autoantigen epitopes in alopecia areata. J Invest Dermatol 2016; 136: 1617–26.
Acknowledgments and disclosures
Acknowledgments: none. Financial support: none. Conflicts of interest: none.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Suzuki, R., Kiniwa, Y., Omodaka, T. et al. Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors. Eur J Dermatol 32, 546–548 (2022). https://doi.org/10.1684/ejd.2022.4315
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2022.4315